Australia's life sciences sector is entering a period of heightened legal and regulatory complexity, with nearly four in five industry leaders expecting their class action exposure to grow over the next three to five years, a major new MinterEllison report finds.
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
AbbVie records a 13-year streak as 'A Great Place to Work'
July 29, 2026 - - Latest News -
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
July 29, 2026 - - Latest News -
AFT Pharmaceuticals sees significant opportunity in a diverse R&D pipeline
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News

